<DOC>
	<DOC>NCT00116376</DOC>
	<brief_summary>AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against the ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of less than 100 nM against p-EGFR, p-ErbB2, and p-KDR (VEGFR2). This study will assess the safety, pharmacokinetic/pharmacodynamic (PK/PD) profiles and clinical activity of AEE788 in a recurrent GBM population.</brief_summary>
	<brief_title>Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Histologically confirmed GBM in first or second recurrence or relapse Adequate hematologic, hepatic and renal function Age ≥ 18 years Karnofsky performance status score ≥ 70% Life expectancy ≥ 12 weeks Peripheral neuropathy &gt; grade 1 Diarrhea &gt; grade 1 Gastrointestinal dysfunction Compromised cardiac function Concurrent severe and/or uncontrolled medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>GBM</keyword>
	<keyword>recurrent/relapse</keyword>
	<keyword>EGFR</keyword>
	<keyword>VEGFR</keyword>
</DOC>